A selective, high affinity 5-HT2B receptor antagonist inhibits visceral hypersensitivity in rats

被引:22
|
作者
Ohashi-Doi, K. [1 ,2 ]
Himaki, D. [2 ]
Nagao, K. [2 ]
Kawai, M. [2 ]
Gale, J. D. [3 ]
Furness, J. B.
Kurebayashi, Y. [2 ]
机构
[1] Univ Melbourne, Dept Anat & Cell Biol, Auton & Pain Lab, Parkville, Vic 3010, Australia
[2] Pfizer Global Res & Dev, Nagoya Labs, Discovery Res, Aichi, Japan
[3] Pfizer Global Res & Dev, Clin Res, Sandwich, Kent, England
来源
NEUROGASTROENTEROLOGY AND MOTILITY | 2010年 / 22卷 / 02期
关键词
5-HT2B receptor antagonist; colon; irritable bowel syndrome; serotonin; visceral hypersensitivity; IRRITABLE-BOWEL-SYNDROME; 5-HYDROXYTRYPTAMINE RECEPTORS; LONGITUDINAL MUSCLE; COLONIC DISTENSION; SEROTONIN; MODEL; DISORDERS; ARTICLE; HYPERALGESIA; SENSITIVITY;
D O I
10.1111/j.1365-2982.2009.01395.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background RS-127445 is a selective, high affinity 5-HT(2B)receptor antagonist. We investigated whether 5-HT(2B)receptor antagonists can reduce colonic visceral hypersensitivity caused by restraint stress or by proximal colonic inflammation. Methods Visceral hypersensitivity was induced in rats by either restraint stress or injection of 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) into the proximal colon. Restraint stress produced a significant increase in numbers of abdominal contractions evoked by colorectal distension (CRD), measured as a quantitative index of visceral nociception in rats. Seven days after TNBS injection, the pain threshold to CRD at the non-inflamed distal colon, that was determined as the minimum pressure required to evoke abdominal cramp, was significantly decreased. The effect of RS-127445 on visceral hypersensitivity was assessed in either naive or TNBS-treated rats. Key Results Oral administration of a selective, high affinity 5-HT(2B)receptor antagonist, RS-127445, significantly inhibited visceral hypersensitivity provoked by restraint stress (35 to 74% inhibition at 1 to 10 mg kg-1). Oral RS-127445 produced a significant suppression of TNBS-induced visceral hypersensitivity (15 to 62% inhibition at 3 to 30 mg kg-1), although it was without significant effect on the visceral nociceptive threshold of naive rats. RS-127445 (1 to 30 mg kg-1, p.o.) also dose-dependently reduced the restraint stress-induced defecation in naive and TNBS-treated rats. Conclusions & Inferences These results suggest that 5-HT(2B)receptors are involved in signaling from the colon in rats in which there is visceral hypersensitivity and that a selective 5-HT(2B)receptor antagonist could have therapeutic potential for the treatment of gut disorders characterized by visceral hypersensitivity.
引用
收藏
页码:e69 / e76
页数:8
相关论文
共 50 条
  • [41] CLONING, DISTRIBUTION AND CHARACTERIZATION OF A HUMAN 5-HT2B RECEPTOR
    BONHAUS, DW
    BACH, C
    DESOUZA, A
    CHAN, HW
    EGLEN, RM
    BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 : P368 - P368
  • [42] SSR149415, a V1b receptor antagonist, inhibits stress-induced visceral hypersensitivity in rats
    Ferrier, Laurent
    Gaultier, Eric
    Gal, Claudine Serradeil-Le
    Pascal, Marc
    Bueno, Lionel
    GASTROENTEROLOGY, 2008, 134 (04) : A544 - A544
  • [43] 5-HT7, but not 5-HT2B, receptors mediate hypotension in vagosympathectomized rats
    Centurión, D
    Glusa, E
    Sánchez-López, A
    Valdivia, LF
    Saxena, PR
    Villalón, CM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 502 (03) : 239 - 242
  • [44] KETANSERIN - A SELECTIVE 5-HT2 RECEPTOR ANTAGONIST
    KOCH, H
    PHARMACY INTERNATIONAL, 1982, 3 (08): : 244 - 245
  • [45] Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties:: Absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis
    Hofmann, C
    Penner, U
    Dorow, R
    Pertz, HH
    Jähnichen, S
    Horowski, R
    Latté, KP
    Palla, D
    Schurad, B
    CLINICAL NEUROPHARMACOLOGY, 2006, 29 (02) : 80 - 86
  • [46] Increased vascular function of 5-HT2B receptors: Use of the 5-HT2B receptor agonist BW723C86
    Watts, SW
    JOURNAL OF VASCULAR RESEARCH, 1999, 36 (05) : 428 - 428
  • [47] GR113808 - A NOVEL, SELECTIVE ANTAGONIST WITH HIGH-AFFINITY AT THE 5-HT4 RECEPTOR
    GALE, JD
    GROSSMAN, CJ
    WHITEHEAD, JWF
    OXFORD, AW
    BUNCE, KT
    HUMPHREY, PPA
    BRITISH JOURNAL OF PHARMACOLOGY, 1994, 111 (01) : 332 - 338
  • [48] Ameliorative effect of chlorpromazine hydrochloride on visceral hypersensitivity in rats: possible involvement of 5-HT2A receptor
    Asano, Teita
    Tanaka, Ken-ichiro
    Tada, Arisa
    Shimamura, Hikaru
    Tanaka, Rikako
    Maruoka, Hiroki
    Mizushima, Tohru
    Takenaga, Mitsuko
    BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 (19) : 3370 - 3381
  • [49] Immunomodulatory effects of AM1030, a topical 5-HT2B receptor antagonist in development for atopic dermatitis
    Palmqvist, N.
    Siller, M.
    Sjodin, A.
    Arozenius, H.
    Wenglen, C.
    Ryde, A.
    Pettersson, L.
    Klint, C.
    Pramhed, A.
    Lotdahl, A.
    Ekstrom, G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S1 - S1
  • [50] BF-1-A novel selective 5-HT2B receptor antagonist blocking neurogenic dural plasma protein extravasation in guinea pigs
    Schmitz, Beate
    Ullmer, Christoph
    Segelcke, Daniel
    Gwarek, Mirella
    Zhu, Xin-Ran
    Luebbert, Hermann
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 751 : 73 - 80